Sfoglia per Autore
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen
2008-01-01 Correale, P.; Fioravanti, A.; Bertoldi, I.; Montagnani, F.; Miracco, C.; Francini, G.
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors
2008-01-01 Petrioli, R.; Pascucci, A.; Francini, E.; Marsili, S.; Fiaschi, A. I.; Civitelli, S.; Tanzini, G.; Battistelli, S.; Lorenzi, M.; Roviello, F.; Francini, G.
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
2008-01-01 Petrioli, R; Pascucci, A; Francini, E; Marsili, S; Sciandivasci, A; Tassi, R; Civitelli, Serenella; Tanzini, G; Lorenzi, Marco; Francini, Guido
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
2008-01-01 Russo, F; Bearz, A; Pampaloni, G; Tirelli, U; Bordonaro, R; Verusio, C; Bian, A. R; Marangolo, M; Bianco, A. R; Grossi, F; Gambi, A; Francini, G; Sogno, G; Manente, P; Gebbia, N; Artioli, F; Ardizzoni, A; Masotti, A; Pozzi, E; Tumolo, S; Passalacqua, R; Casartelli, C; Montanari, F; Colucci, G; Barbera, S; Ricci, S; Trodella, L; Valentini, V; Mantovani, G; Ravaioli, A; Monfardini, S; Barni, S; Felletti, R; Testora, F; Aglietta, M; Ardizzoia, A; Bollina, R; Cruciani, G; Pasquini, E.
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial)
2008-01-01 Correale, P.; Tagliaferri, P.; Fioravanti, A.; DEL VECCHIO, M. T.; Remondo, C.; Montagnani, F.; Rotundo, M. S.; Ginanneschi, C.; Martellucci, I.; Francini, E.; Cusi, M. G.; Tassone, P.; Francini, G.
Autoimmunity predicts prolonged survival in colon cancer patients undergoing GOLFIG biochemotherapy
2007-01-01 Correale, P.; Tagliaferri, P.; Montagnani, F.; Remondo, C.; Intrivici, C.; Fulfaro, F.; Tsang, K. Y.; Tassone, P.; Rotundo, M. S.; Venuta, S.; Francini, G.
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy
2007-01-01 Petrioli, R.; Paolelli, L.; Francini, E.; Marsili, S.; Pascucci, A.; Sciandivasci, A.; de Rubertis, G.; Barbanti, G.; Manganelli, A.; Salvestrini, F.; Francini, G.
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation
2007-01-01 Correale, P.; Sciandivasci, A.; Intrivici, C.; Pascucci, A.; DEL VECCHIO, M. T.; Marsili, S.; Savelli, V.; Voltolini, L.; DI BISCEGLIE, M.; Guarnieri, A.; Gotti, G.; Francini, G.
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane
2007-01-01 Gonnelli, S.; Cadirni, A.; Caffarelli, C.; Petrioli, R.; Montagnani, A.; Franci, M. B.; Lucani, B.; Francini, G.; Nuti, R.
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel
2007-01-01 Petrioli, R.; Pascucci, A.; Francini, E.; Marsili, S.; Sciandivasci, A.; De Rubertis, G.; Barbanti, G.; Manganelli, A.; Salvestrini, F.; Francini, G.
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
2007-01-01 Sargent, D. J; Patiyil, S; Yothers, G; Haller, D. G; Gray, R; Benedetti, J; Buyse, M; Labianca, R; Seitz, J. F; O'Callaghan, C. J; Francini, G; Grothey, A; O'Connell, M; Catalano, P. J; Kerr, D; Green, E; Wieand, H. S; Goldberg, R. M; De Gramont, A.
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.
2007-01-01 Petrioli, R; Paolelli, L; Francini, E; Manganelli, A; Salvestrini, F; Francini, Guido
A Poly-epitopic peptide vaccine against the thymidylate synthase (TS). A synergistic therapeutic combination with fluoropyrimidine-based-chemotherapy
2006-01-01 Correale, P.; Cusi, M. G.; Del Vecchio, M. T.; La Placa, M.; Di Genova, G.; Montagnani, F.; Remondo, C.; Bonmassar, E.; Aquino, A.; Prete, S. P.; Giorgi, G.; Francini, G.
Poly-epitope peptide derived from Thymidylate Synthase having immunological and anti-tumour activity.
2006-01-01 Correale, P; Cusi, MARIA GRAZIA; Francini, Guido; Giorgi, G.
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
2006-01-01 Francini, Guido; Petrioli, R; Montagnani, A; Cadirni, A; Campagna, MARIA STELLA; Francini, E; Gonnelli, Stefano
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience
2006-01-01 Correale, P.; Cusi, MARIA GRAZIA; Micheli, Lucia; Nencini, Cristina; DEL VECCHIO, MARIA TERESA; Torino, F.; Aquino, A.; Bonmassar, E.; Francini, Guido; Giorgi, Giorgio
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer
2006-01-01 Petrioli, R.; Paolelli, L.; Marsili, S.; Civitelli, S.; Francini, E.; Cioppa, T.; Roviello, F.; Nettuno, R.; Intrivici, C.; Tanzini, G.; Lorenzi, M.; Francini, G.
Chemo-immunotherapy regimen with gemcitabine + FOLFOX 4 (GOLF) followed by subcutaneous (sc) granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2). Results from a multicenter phase II trial in colon carcinoma patients
2006-01-01 Correale, P.; Remondo, C.; Montagnani, F.; Rotundo, Ms.; Marsili, S.; Laplaca, M.; Tassone, P.; Tagliaferri, P.; Venuta, S.; Francini, G.
GOLF induces apoptosis through multi-chaperone complex inactivation and increased raf-1 ubiquitin-dependent degradation
2006-01-01 Caraglia, Michele; Marra, Monica; Budillon, Alfredo; Meo, Giuseppina; Remondo, Cinzia; Francini, Guido; Giordano, Antonio; Abbruzzese, Alberto; Correale, Pierpaolo
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients
2006-01-01 Correale, P.; Cerretani, D.; Remondo, C.; Martellucci, I.; Marsili, S.; La Placa, M.; Sciandivasci, A.; Paolelli, L.; Pascucci, A.; Rossi, M.; Di Bisceglie, M.; Giorgi, G.; Gotti, G.; Francini, G.
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen | 1-gen-2008 | Correale, P.; Fioravanti, A.; Bertoldi, I.; Montagnani, F.; Miracco, C.; Francini, G. | - | |
| Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors | 1-gen-2008 | Petrioli, R.; Pascucci, A.; Francini, E.; Marsili, S.; Fiaschi, A. I.; Civitelli, S.; Tanzini, G.; Battistelli, S.; Lorenzi, M.; Roviello, F.; Francini, G. | - | |
| Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. | 1-gen-2008 | Petrioli, R; Pascucci, A; Francini, E; Marsili, S; Sciandivasci, A; Tassi, R; Civitelli, Serenella; Tanzini, G; Lorenzi, Marco; Francini, Guido | - | |
| Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer | 1-gen-2008 | Russo, F; Bearz, A; Pampaloni, G; Tirelli, U; Bordonaro, R; Verusio, C; Bian, A. R; Marangolo, M; Bianco, A. R; Grossi, F; Gambi, A; Francini, G; Sogno, G; Manente, P; Gebbia, N; Artioli, F; Ardizzoni, A; Masotti, A; Pozzi, E; Tumolo, S; Passalacqua, R; Casartelli, C; Montanari, F; Colucci, G; Barbera, S; Ricci, S; Trodella, L; Valentini, V; Mantovani, G; Ravaioli, A; Monfardini, S; Barni, S; Felletti, R; Testora, F; Aglietta, M; Ardizzoia, A; Bollina, R; Cruciani, G; Pasquini, E. | - | |
| Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial) | 1-gen-2008 | Correale, P.; Tagliaferri, P.; Fioravanti, A.; DEL VECCHIO, M. T.; Remondo, C.; Montagnani, F.; Rotundo, M. S.; Ginanneschi, C.; Martellucci, I.; Francini, E.; Cusi, M. G.; Tassone, P.; Francini, G. | - | |
| Autoimmunity predicts prolonged survival in colon cancer patients undergoing GOLFIG biochemotherapy | 1-gen-2007 | Correale, P.; Tagliaferri, P.; Montagnani, F.; Remondo, C.; Intrivici, C.; Fulfaro, F.; Tsang, K. Y.; Tassone, P.; Rotundo, M. S.; Venuta, S.; Francini, G. | - | |
| Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy | 1-gen-2007 | Petrioli, R.; Paolelli, L.; Francini, E.; Marsili, S.; Pascucci, A.; Sciandivasci, A.; de Rubertis, G.; Barbanti, G.; Manganelli, A.; Salvestrini, F.; Francini, G. | - | |
| Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation | 1-gen-2007 | Correale, P.; Sciandivasci, A.; Intrivici, C.; Pascucci, A.; DEL VECCHIO, M. T.; Marsili, S.; Savelli, V.; Voltolini, L.; DI BISCEGLIE, M.; Guarnieri, A.; Gotti, G.; Francini, G. | - | |
| Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane | 1-gen-2007 | Gonnelli, S.; Cadirni, A.; Caffarelli, C.; Petrioli, R.; Montagnani, A.; Franci, M. B.; Lucani, B.; Francini, G.; Nuti, R. | - | |
| Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel | 1-gen-2007 | Petrioli, R.; Pascucci, A.; Francini, E.; Marsili, S.; Sciandivasci, A.; De Rubertis, G.; Barbanti, G.; Manganelli, A.; Salvestrini, F.; Francini, G. | - | |
| End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. | 1-gen-2007 | Sargent, D. J; Patiyil, S; Yothers, G; Haller, D. G; Gray, R; Benedetti, J; Buyse, M; Labianca, R; Seitz, J. F; O'Callaghan, C. J; Francini, G; Grothey, A; O'Connell, M; Catalano, P. J; Kerr, D; Green, E; Wieand, H. S; Goldberg, R. M; De Gramont, A. | - | |
| Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. | 1-gen-2007 | Petrioli, R; Paolelli, L; Francini, E; Manganelli, A; Salvestrini, F; Francini, Guido | - | |
| A Poly-epitopic peptide vaccine against the thymidylate synthase (TS). A synergistic therapeutic combination with fluoropyrimidine-based-chemotherapy | 1-gen-2006 | Correale, P.; Cusi, M. G.; Del Vecchio, M. T.; La Placa, M.; Di Genova, G.; Montagnani, F.; Remondo, C.; Bonmassar, E.; Aquino, A.; Prete, S. P.; Giorgi, G.; Francini, G. | - | |
| Poly-epitope peptide derived from Thymidylate Synthase having immunological and anti-tumour activity. | 1-gen-2006 | Correale, P; Cusi, MARIA GRAZIA; Francini, Guido; Giorgi, G. | - | |
| Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. | 1-gen-2006 | Francini, Guido; Petrioli, R; Montagnani, A; Cadirni, A; Campagna, MARIA STELLA; Francini, E; Gonnelli, Stefano | - | |
| Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience | 1-gen-2006 | Correale, P.; Cusi, MARIA GRAZIA; Micheli, Lucia; Nencini, Cristina; DEL VECCHIO, MARIA TERESA; Torino, F.; Aquino, A.; Bonmassar, E.; Francini, Guido; Giorgi, Giorgio | - | |
| FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer | 1-gen-2006 | Petrioli, R.; Paolelli, L.; Marsili, S.; Civitelli, S.; Francini, E.; Cioppa, T.; Roviello, F.; Nettuno, R.; Intrivici, C.; Tanzini, G.; Lorenzi, M.; Francini, G. | - | |
| Chemo-immunotherapy regimen with gemcitabine + FOLFOX 4 (GOLF) followed by subcutaneous (sc) granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2). Results from a multicenter phase II trial in colon carcinoma patients | 1-gen-2006 | Correale, P.; Remondo, C.; Montagnani, F.; Rotundo, Ms.; Marsili, S.; Laplaca, M.; Tassone, P.; Tagliaferri, P.; Venuta, S.; Francini, G. | - | |
| GOLF induces apoptosis through multi-chaperone complex inactivation and increased raf-1 ubiquitin-dependent degradation | 1-gen-2006 | Caraglia, Michele; Marra, Monica; Budillon, Alfredo; Meo, Giuseppina; Remondo, Cinzia; Francini, Guido; Giordano, Antonio; Abbruzzese, Alberto; Correale, Pierpaolo | - | |
| A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients | 1-gen-2006 | Correale, P.; Cerretani, D.; Remondo, C.; Martellucci, I.; Marsili, S.; La Placa, M.; Sciandivasci, A.; Paolelli, L.; Pascucci, A.; Rossi, M.; Di Bisceglie, M.; Giorgi, G.; Gotti, G.; Francini, G. | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile